CSL Limited (ASX:CSL) Insider Megan Clark Acquires 200 Shares

CSL Limited (ASX:CSL) insider Megan Clark purchased 200 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were purchased at an average cost of A$250.06 ($159.27) per share, with a total value of A$50,012.00 ($31,854.78).

Megan Clark also recently made the following trade(s):

• On Wednesday, February 19th, Megan Clark acquired 132 shares of CSL stock. The stock was purchased at an average cost of A$264.85 ($168.69) per share, with a total value of A$34,959.94 ($22,267.48).

CSL Price Performance

The company has a market capitalization of $77.43 billion, a P/E ratio of 28.02, a PEG ratio of 1.29 and a beta of 0.32. The company has a debt-to-equity ratio of 64.46, a current ratio of 1.86 and a quick ratio of 1.68.

CSL Increases Dividend

The firm also recently announced a Interim dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Tuesday, April 8th will be given a $2.073 dividend. This represents a dividend yield of 0.81%. This is a positive change from CSL’s previous Interim dividend of $1.83. The ex-dividend date of this dividend is Sunday, March 9th. CSL’s dividend payout ratio is presently 50.38%.

About CSL

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.